-
1
-
-
13544275273
-
The polycythemias
-
Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Philadelphia, PA: Churchill Livingstone
-
Hoffman R, Xu M, Finazzi G, Barbui T. The polycythemias. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. Philadelphia, PA: Churchill Livingstone; 2008:1073-1108.
-
(2008)
Hematology: Basic Principles and Practice
, pp. 1073-1108
-
-
Hoffman, R.1
Xu, M.2
Finazzi, G.3
Barbui, T.4
-
2
-
-
0141498506
-
Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders
-
Mesa RA. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders. Int J Hematol. 2002;76(Suppl 2):193-203.
-
(2002)
Int J Hematol.
, vol.76
, Issue.SUPPL. 2
, pp. 193-203
-
-
Mesa, R.A.1
-
3
-
-
0037114625
-
Polycythemia vera: Myths, mechanisms, and management
-
DOI 10.1182/blood-2001-12-0349
-
Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100(13):4272-4290. (Pubitemid 35429665)
-
(2002)
Blood
, vol.100
, Issue.13
, pp. 4272-4290
-
-
Spivak, J.L.1
-
4
-
-
9644275709
-
Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders
-
DOI 10.1016/j.blre.2004.02.002, PII S0268960X04000141
-
Kralovics R, Skoda RC. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev. 2005;19(1):1-13. (Pubitemid 39574245)
-
(2005)
Blood Reviews
, vol.19
, Issue.1
, pp. 1-13
-
-
Kralovics, R.1
Skoda, R.C.2
-
5
-
-
84883185991
-
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a
-
Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a. Blood. 2013;122(6):893-901.
-
(2013)
Blood.
, vol.122
, Issue.6
, pp. 893-901
-
-
Quintás-Cardama, A.1
Abdel-Wahab, O.2
Manshouri, T.3
-
6
-
-
54049141336
-
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
-
Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8):3065-3072.
-
(2008)
Blood.
, vol.112
, Issue.8
, pp. 3065-3072
-
-
Kiladjian, J.J.1
Cassinat, B.2
Chevret, S.3
-
7
-
-
56249104095
-
Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms
-
Kiladjian J-J, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia. 2008;22(11):1990-1998.
-
(2008)
Leukemia.
, vol.22
, Issue.11
, pp. 1990-1998
-
-
Kiladjian, J.-J.1
Chomienne, C.2
Fenaux, P.3
-
8
-
-
79955947379
-
The renaissance of interferon therapy for the treatment of myeloid malignancies
-
Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011;117(18):4706-4715.
-
(2011)
Blood.
, vol.117
, Issue.18
, pp. 4706-4715
-
-
Kiladjian, J.J.1
Mesa, R.A.2
Hoffman, R.3
-
9
-
-
33746059048
-
High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a
-
DOI 10.1182/blood-2006-03-009860
-
Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a. Blood. 2006;108(6):2037-2040. (Pubitemid 44395018)
-
(2006)
Blood
, vol.108
, Issue.6
, pp. 2037-2040
-
-
Kiladjian, J.-J.1
Cassinat, B.2
Turlure, P.3
Cambier, N.4
Roussel, M.5
Bellucci, S.6
Menot, M.-L.7
Massonnet, G.8
Dutel, J.-L.9
Ghomari, K.10
Rousselot, P.11
Grange, M.-J.12
Chait, Y.13
Vainchenker, W.14
Parquet, N.15
Abdelkader-Aljassem, L.16
Bernard, J.-F.17
Rain, J.-D.18
Chevret, S.19
Chomienne, C.20
Fenaux, P.21
more..
-
10
-
-
33746307253
-
Long-term effects of the treatment of polycythemia vera with recombinant interferon-α
-
DOI 10.1002/cncr.22026
-
Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-α. Cancer. 2006;107(3):451-458. (Pubitemid 44107203)
-
(2006)
Cancer
, vol.107
, Issue.3
, pp. 451-458
-
-
Silver, R.T.1
-
11
-
-
73949090770
-
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera
-
Quintás-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27(32):5418-5424.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.32
, pp. 5418-5424
-
-
Quintás-Cardama, A.1
Kantarjian, H.2
Manshouri, T.3
-
12
-
-
81255210738
-
A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms
-
Hasselbalch HC. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol. 2011;4(6):637-655.
-
(2011)
Expert Rev Hematol.
, vol.4
, Issue.6
, pp. 637-655
-
-
Hasselbalch, H.C.1
-
13
-
-
84867750834
-
Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells
-
Lu M, Wang X, Li Y, et al. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells. Blood. 2012;120(15):3098-3105.
-
(2012)
Blood.
, vol.120
, Issue.15
, pp. 3098-3105
-
-
Lu, M.1
Wang, X.2
Li, Y.3
-
14
-
-
78549243371
-
Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells
-
Lu M, Wang J, Li Y, et al. Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells. Blood. 2010;116(20):4284-4287.
-
(2010)
Blood.
, vol.116
, Issue.20
, pp. 4284-4287
-
-
Lu, M.1
Wang, J.2
Li, Y.3
-
15
-
-
84863652338
-
Roles of p53 in various biological aspects of hematopoietic stem cells
-
Nii T, Marumoto T, Tani K. Roles of p53 in various biological aspects of hematopoietic stem cells. J Biomed Biotechnol. 2012;2012:903435.
-
(2012)
J Biomed Biotechnol
, vol.2012
, pp. 903435
-
-
Nii, T.1
Marumoto, T.2
Tani, K.3
-
16
-
-
0033060788
-
IARC p53 mutation database: A relational database to compile and analyze p53 mutations in human tumors and cell lines
-
DOI 10.1002/(SICI)1098-1004(1999)14:1<1::AID-HUMU1
-
Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P; International Agency for Research on Cancer. IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. Hum Mutat. 1999;14(1):1-8. (Pubitemid 29309938)
-
(1999)
Human Mutation
, vol.14
, Issue.1
, pp. 1-8
-
-
Hernandez-Boussard, T.1
Rodriguez-Tome, P.2
Montesano, R.3
Hainaut, P.4
-
17
-
-
0036785106
-
N-ras and p53 gene mutations in Japanese patients with myeloproliferative disorders
-
Tsurumi S, Nakamura Y, Maki K, et al. N-ras and p53 gene mutations in Japanese patients with myeloproliferative disorders. Am J Hematol. 2002;71(2):131-133.
-
(2002)
Am J Hematol.
, vol.71
, Issue.2
, pp. 131-133
-
-
Tsurumi, S.1
Nakamura, Y.2
Maki, K.3
-
18
-
-
79551542848
-
p53 lesions in leukemic transformation
-
Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. p53 lesions in leukemic transformation. N Engl J Med. 2011;364(5):488-490.
-
(2011)
N Engl J Med.
, vol.364
, Issue.5
, pp. 488-490
-
-
Harutyunyan, A.1
Klampfl, T.2
Cazzola, M.3
Kralovics, R.4
-
19
-
-
1242316989
-
STAT-1 Interacts with p53 to Enhance DNA Damage-induced Apoptosis
-
DOI 10.1074/jbc.M302637200
-
Townsend PA, Scarabelli TM, Davidson SM, Knight RA, Latchman DS, Stephanou A. STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem. 2004;279(7):5811-5820. (Pubitemid 38220612)
-
(2004)
Journal of Biological Chemistry
, vol.279
, Issue.7
, pp. 5811-5820
-
-
Townsend, P.A.1
Scarabelli, T.M.2
Davidson, S.M.3
Knight, R.A.4
Latchman, D.S.5
Stephanou, A.6
-
20
-
-
77952955507
-
Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway
-
Lu M, Zhang W, Li Y, et al. Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol. 2010;38(6):472-480.
-
(2010)
Exp Hematol.
, vol.38
, Issue.6
, pp. 472-480
-
-
Lu, M.1
Zhang, W.2
Li, Y.3
-
21
-
-
78650638268
-
SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis
-
Li Y, Matsumori H, Nakayama Y, et al. SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis. Genes Cells. 2011;16(1):34-45.
-
(2011)
Genes Cells.
, vol.16
, Issue.1
, pp. 34-45
-
-
Li, Y.1
Matsumori, H.2
Nakayama, Y.3
-
22
-
-
33845901313
-
MDM2 inhibitors for cancer therapy
-
DOI 10.1016/j.molmed.2006.11.002, PII S1471491406002590
-
Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med. 2007;13(1):23-31. (Pubitemid 46027725)
-
(2007)
Trends in Molecular Medicine
, vol.13
, Issue.1
, pp. 23-31
-
-
Vassilev, L.T.1
-
23
-
-
79551474361
-
MDM2 and MDMX in cancer and development
-
Marine JC. MDM2 and MDMX in cancer and development. Curr Top Dev Biol. 2011;94:45-75.
-
(2011)
Curr Top Dev Biol.
, vol.94
, pp. 45-75
-
-
Marine, J.C.1
-
24
-
-
84858008200
-
JAK2 (V617F) negatively regulates p53 stabilization by enhancing MDM2 via la expression in myeloproliferative neoplasms
-
Nakatake M, Monte-Mor B, Debili N, et al. JAK2 (V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene. 2012;31(10):1323-1333.
-
(2012)
Oncogene.
, vol.31
, Issue.10
, pp. 1323-1333
-
-
Nakatake, M.1
Monte-Mor, B.2
Debili, N.3
-
25
-
-
10744221485
-
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
-
DOI 10.1126/science.1092472
-
Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303(5659):844-848. (Pubitemid 38174664)
-
(2004)
Science
, vol.303
, Issue.5659
, pp. 844-848
-
-
Vassilev, L.T.1
Vu, B.T.2
Graves, B.3
Carvajal, D.4
Podlaski, F.5
Filipovic, Z.6
Kong, N.7
Kammlott, U.8
Lukacs, C.9
Klein, C.10
Fotouhi, N.11
Liu, E.A.12
-
26
-
-
79960381235
-
A multi-center, open-label, phase I study of single agent RG7112, a first in class p53-MDM2 antagonist, in patients with relapsed/refractory acute myeloid and lymphoid leukemias (AML/ALL) and refractory chronic lymphocytic leukemia/small cell lymphocytic lymphomas (CLL/SCLL)
-
Andreeff M, Kojima K, Padmanabhan S, et al. A multi-center, open-label, phase I study of single agent RG7112, a first in class p53-MDM2 antagonist, in patients with relapsed/refractory acute myeloid and lymphoid leukemias (AML/ALL) and refractory chronic lymphocytic leukemia/small cell lymphocytic lymphomas (CLL/SCLL). ASH Annual Abstracts. 2010;116:657.
-
(2010)
ASH Annual Abstracts.
, vol.116
, pp. 657
-
-
Andreeff, M.1
Kojima, K.2
Padmanabhan, S.3
-
27
-
-
0002069670
-
Chronic idiopathic myelofibrosis
-
Jaffe ES, Harris N, Stan N, Vardiman JW, eds. Washington, DC: IARC Press
-
Jaffe ES, Harris N, Stan N, et al. Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris N, Stan N, Vardiman JW, eds. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. Washington, DC: IARC Press; 2001:35-38.
-
(2001)
World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues
, pp. 35-38
-
-
Jaffe, E.S.1
Harris, N.2
Stan, N.3
-
28
-
-
84868612626
-
Spleens of myelofibrosis patients contain malignant hematopoietic stem cells
-
Wang X, Prakash S, Lu M, et al. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest. 2012;122(11):3888-3899.
-
(2012)
J Clin Invest.
, vol.122
, Issue.11
, pp. 3888-3899
-
-
Wang, X.1
Prakash, S.2
Lu, M.3
-
29
-
-
33750611344
-
Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera
-
Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood. 2006;108(9):3128-3134.
-
(2006)
Blood.
, vol.108
, Issue.9
, pp. 3128-3134
-
-
Ishii, T.1
Bruno, E.2
Hoffman, R.3
Xu, M.4
-
31
-
-
84897131066
-
JAK2 mutants (e.G., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
-
Gäbler K, Behrmann I, Haan C. JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAK-STAT. 2013;2(3):e25025.
-
(2013)
JAK-STAT.
, vol.2
, Issue.3
-
-
Gäbler, K.1
Behrmann, I.2
Haan, C.3
-
32
-
-
84887736491
-
Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis
-
Gowin K, Mesa R. Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis. Expert Opin Investig Drugs. 2013;22(12):1603-1611.
-
(2013)
Expert Opin Investig Drugs.
, vol.22
, Issue.12
, pp. 1603-1611
-
-
Gowin, K.1
Mesa, R.2
-
33
-
-
84872808860
-
p53 as a target in myeloproliferative neoplasms
-
Lu M, Hoffman R. p53 as a target in myeloproliferative neoplasms. Oncotarget. 2012;3(10):1052-1053.
-
(2012)
Oncotarget.
, vol.3
, Issue.10
, pp. 1052-1053
-
-
Lu, M.1
Hoffman, R.2
-
34
-
-
84880944672
-
Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha
-
Stauffer Larsen T, Iversen KF, Hansen E, et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res. 2013;37(9):1041-1045.
-
(2013)
Leuk Res.
, vol.37
, Issue.9
, pp. 1041-1045
-
-
Stauffer Larsen, T.1
Iversen, K.F.2
Hansen, E.3
-
35
-
-
84879728130
-
Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera
-
Mullally A, Bruedigam C, Poveromo L, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood. 2013;121(18):3692-3702.
-
(2013)
Blood.
, vol.121
, Issue.18
, pp. 3692-3702
-
-
Mullally, A.1
Bruedigam, C.2
Poveromo, L.3
-
36
-
-
84886850069
-
JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNa
-
Hasan S, Lacout C, Marty C, et al. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNa. Blood. 2013;122(8):1464-1477.
-
(2013)
Blood.
, vol.122
, Issue.8
, pp. 1464-1477
-
-
Hasan, S.1
Lacout, C.2
Marty, C.3
-
37
-
-
79959232873
-
Recombinant interferon-a may retard progression of early primary myelofibrosis: A preliminary report
-
Silver RT, Vandris K, Goldman JJ. Recombinant interferon-a may retard progression of early primary myelofibrosis: a preliminary report. Blood. 2011;117(24):6669-6672.
-
(2011)
Blood.
, vol.117
, Issue.24
, pp. 6669-6672
-
-
Silver, R.T.1
Vandris, K.2
Goldman, J.J.3
-
38
-
-
67649976491
-
PEG-IFN-α-2a therapy in patients with myelofibrosis: A study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myéloprolifératifs (FIM)
-
Ianotto JC, Kiladjian JJ, Demory JL, et al. PEG-IFN-α-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myé loprolifératifs (FIM). Br J Haematol. 2009;146(2):223-225.
-
(2009)
Br J Haematol.
, vol.146
, Issue.2
, pp. 223-225
-
-
Ianotto, J.C.1
Kiladjian, J.J.2
Demory, J.L.3
|